

Table 1. Current Clinical Trials

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
ADOPTIVE IMMUNOTHERAPY				
Reconstitution of HIV-specific immunity against HIV	NCT02563509	Guangzhou 8th People's Hospital	Phase I/II	December 2016
HXTC: HIV 1 antigen expanded specific T cell therapy	NCT02208167	University of North Carolina, Chapel Hill	Phase I	September 2018
ANTIBODIES				
vedolizumab (anti- $\alpha_4\beta_7$ integrin antibody)	NCT03147859 (not yet open for enrollment)	Ottawa Hospital Research Institute	Phase II	December 2018
VRC01 (broadly neutralizing monoclonal antibody)	NCT02664415 (closed to enrollment)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase II	July 2017
3BNC117 (broadly neutralizing monoclonal antibody)	NCT02446847 (closed to enrollment)	Rockefeller University	Phase I/II	March 2018
3BNC117	NCT02588586 (closed to enrollment)	Rockefeller University	Phase I/II	March 2018
10-1074 (broadly neutralizing monoclonal antibody)	NCT02511990 (closed to enrollment)	Rockefeller University	Phase I	July 2017
3BNC117 + 10-1074	NCT02825797	Rockefeller University	Phase I	June 2018
PGT121	NCT02960581 (enrolling by invitation only)	International AIDS Vaccine Initiative	Phase I	March 2018
vedolizumab (anti- $\alpha_4\beta_7$ integrin antibody)	NCT02788175	NIAID	Phase I	May 2020
VRC01LS (long-acting broadly neutralizing monoclonal antibody)	NCT02840474	NIAID	Phase I	August 2018
VRC01 in acute HIV infection	NCT02591420	NIAID	Phase I	December 2016
VRC01	NCT02471326 (closed to enrollment)	NIAID	Phase I	June 2018
ANTI-FIBROTIC				
losartan	NCT01852942	University of Minnesota	Phase II	July 2018
telmisartan	NCT02170246	Yale University	Phase I	February 2019

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
ANTI-INFLAMMATORY				
canakinumab (IL-1 β inhibitor)	NCT02272946	University of California, San Francisco	Phase II	June 2018
CC-11050 (phosphodiesterase-4 inhibitor)	NCT02652546	NIAID	Phase I	October 2017
metformin	NCT02659306	McGill University Health Center	Phase I	October 2017
ANTIRETROVIRAL THERAPY				
dolutegravir in reservoirs	NCT02924389	Emory University	Phase N/A	June 2020
HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen	NCT02513147 (closed to enrollment)	Hospital Universitari Vall d'Hebron Research Institute	Phase IV	November 2016
ABX464	NCT02735863	Abivax S.A.	Phase II	October 2016
ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS				
emtricitabine + rilpivirine + tenofovir	NCT01777997 (closed to enrollment)	AIDS Clinical Trials Group/NIAID	Phase IV	May 2017
COMBINATIONS				
maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide	NCT02961829 (closed to enrollment)	Federal University of São Paulo	Not listed	July 2017
Perturbing of HIV reservoir with immune stimulation: Fluarix, Pneumovax vaccines	NCT02707692	University of California, San Diego	Not listed	January 2021
Impact of Sirolimus and maraviroc on CCR5 expression and the HIV-1 reservoir in HIV+ kidney transplant recipients	NCT02990312 (not yet open for enrollment)	University of Maryland	Phase IV	July 2020
ROADMAP: romidepsin + 3BNC117	NCT02850016	Rockefeller University	Phase IIa	December 2018
eCLEAR: romidepsin + 3BNC117	NCT03041012	Aarhus University Hospital	Phase II	August 2019
panobinostat + pegylated interferon-alpha2a	NCT02471430	Massachusetts General Hospital	Phase II	February 2020
Research In Viral Eradication of HIV Reservoirs (RIVER): ART, ChAdV63.HIVconsv & MVA.HIVconsv vaccines, vorinostat	NCT02336074 UK CPMS18010 (closed to enrollment)	Imperial College London	Phase II	July 2018
SB-728mR-T (autologous CD4 T cells genetically modified at the CCR5 gene) + cyclophosphamide	NCT02225665 (closed to enrollment)	Sangamo BioSciences	Phase I/II	June 2018

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
COMBINATIONS (Cont.)				
SB-728-T + cyclophosphamide	NCT01543152 (closed to enrollment)	Sangamo BioSciences	Phase I/II	September 2016
AGS-004 + vorinostat	NCT02707900	NIAID	Phase I	December 2019
DCV3 (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon	NCT02767193	Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica	Phase I	June 2018
MVA.HIVconsv + romidepsin	NCT02616874 (closed to enrollment)	IrsiCaixa	Phase I	October 2017
SB-728mR-T + cyclophosphamide	NCT02388594	University of Pennsylvania	Phase I	December 2018
CD4-ZETA gene-modified T cells +/- interleukin-2 (IL-2)	NCT01013415 (closed to enrollment)	University of Pennsylvania	Phase I	June 2016
GENE THERAPIES				
Cal-1: Dual anti-HIV gene transfer construct	ACTRN12615000763549	Calimmune	Phase I/II	N/A
Cal-1: Dual anti-HIV gene transfer construct	NCT01734850 (closed to enrollment) NCT02390297 (long term safety phase)	Calimmune	Phase I/II	June 2015 January 2032
VRX496 (gene-modified autologous CD4 T cells)	NCT00295477 (closed to enrollment)	University of Pennsylvania	Phase I/II	December 2020
SB-728mR-HSPC (autologous hematopoietic stem/progenitor cells genetically modified at the CCR5 gene)	NCT02500849	City of Hope Medical Center	Phase I	July 2018
MazF-T (redirected MazF-CD4 autologous T cells)	NCT01787994 (closed to enrollment)	Takara Bio/University of Pennsylvania	Phase I	December 2016
C34-CXCR4 (autologous CD4 T cells gene-modified to express HIV-inhibiting peptide C34)	NCT03020524	University of Pennsylvania	Phase 0	January 2018
GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS				
Stem cells gene-modified with CCR5 shRNA/TRIM5alpha/TAR decoy	NCT02797470	AIDS Malignancy Consortium	Phase I/II	September 2019

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS (Cont.)				
Stem cells gene-modified with M87o vector encoding HIV-inhibiting C46 peptide	NCT00858793 (suspended)	Universitätsklinikum Hamburg-Eppendorf	Phase I/II	October 2017
Stem cells gene-modified with C46/CCR5/P140K	NCT02343666	Fred Hutchinson Cancer Research Center	Phase I	August 2020
Stem cells gene-modified with Cal-1	NCT02378922 (suspended)	Fred Hutchinson Cancer Research Center	Phase I	June 2019
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	NCT02337985	City of Hope Medical Center	Not listed	June 2031
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ) + busulfan	NCT01961063	City of Hope Medical Center	Not listed	October 2030
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	NCT00569985 (closed to enrollment)	City of Hope Medical Center	Not listed	December 2015
HORMONES				
somatotropin (human growth hormone)	NCT03091374	McGill University Health Center	Phase II	June 2019
IMAGING STUDIES				
Radiolabeled broadly neutralizing anti-HIV antibody 3BNC117 + Copper-64 radio isotope followed by MRI/PET scanning to detect HIV in vivo	NCT03063788 (not yet open for enrollment)	Bayside Health	Phase I	December 2017
IMMUNE CHECKPOINT INHIBITORS				
durvalumab (anti-PD-L1 antibody) in solid tumors	NCT03094286	Spanish Lung Cancer Group	Phase II	April 2022
nivolumab (anti-PD-1 antibody) + ipilimumab (anti-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors	NCT02408861	National Cancer Institute (NCI)	Phase I	December 2020
pembrolizumab (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms	NCT02595866	National Cancer Institute (NCI)	Phase I	April 2018
JANUS KINASE INHIBITORS				
ruxolitinib	NCT02475655	NIAID	Phase II	October 2016

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
LATENCY-REVERSING AGENTS				
Chidamide	NCT02902185	Tang-Du Hospital	Phase II/III	December 2018
Poly-ICLC (TLR-3 agonist)	NCT02071095 (closed to enrollment)	Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc.	Phase I/II	June 2017
romidepsin (HDAC inhibitor)	NCT01933594	AIDS Clinical Trials Group/NIAID/Gilead	Phase I/II	August 2017
GS-9620 (TLR-7 agonist) in ART-treated HIV controllers	NCT03060447	Gilead Sciences	Phase Ib	September 2018
GS-9620 (TLR-7 agonist)	NCT02858401	Gilead Sciences	Phase Ib	December 2016
ALT-803 (recombinant human super agonist interleukin-15 complex)	NCT02191098	University of Minnesota - Clinical and Translational Science Institute	Phase I	June 2016
Kansui (traditional Chinese medicine containing ingenols)	NCT02531295 (suspended)	UCSF	Phase I	December 2019
mTOR INHIBITORS				
Impact of Everolimus on HIV persistence post kidney or liver transplant	NCT02429869	UCSF	Phase IV	June 2017
Sirolimus	NCT02440789	ACTG	Phase I/II	December 2016
PROTEASOME INHIBITORS				
ixazomib	NCT02946047	Nathan W. Cummins, M.D.	Phase I/II	September 2019
STEM CELL TRANSPLANTATION				
HIVECT : HIV eradication through cord-blood transplantation	NCT02923076	Puerta de Hierro University Hospital	N/A	December 2018
IMPAACT P1107 : Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease	NCT02140944	IMPAACT/NIAID/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	March 2023
BMT CTN 0903 : Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection	NCT01410344 (closed to enrollment)	National Heart, Lung, and Blood Institute (NHLBI)/National Cancer Institute (NCI)/ Blood and Marrow Transplant Clinical Trials Network	Phase II	November 2015

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
STEM CELL TRANSPLANTATION (Cont.)				
Immune response after stem cell transplant in HIV-positive patients with hematologic cancer	NCT00968630 (closed to enrollment)	Fred Hutchinson Cancer Research Center	Phase II	September 2017
Maraviroc in HIV-1+ individuals requiring allogeneic hematopoietic cell transplant	NCT03118661 (not yet open for enrollment)	Washington University School of Medicine	Phase I	May 2025
THERAPEUTIC VACCINES				
iHIVARNA-01 (TriMix & HIV antigen naked messenger RNA)	NCT02888756	Rob Gruters, Erasmus Medical Center	Phase IIa	November 2017
GTU-multiHIV + LIPO-5 (DNA + lipopeptide vaccines)	NCT01492985 (closed to enrollment)	French National Institute for Health and Medical Research/French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	Phase II	October 2017
GTU-MultiHIV B-clade + MVA HIV-B (DNA + viral vector vaccines)	NCT02972450 (not yet open for enrollment)	Inserm/ANRS	Phase II	July 2018
VAC-3S (peptide-based vaccine)	NCT02041247 (closed to enrollment)	InnaVirVax	Phase II	November 2016
VAC-3S	NCT02390466 (closed to enrollment)	InnaVirVax	Phase I/IIa	April 2017
Tat Oyi (protein-based vaccine)	NCT01793818 (closed to enrollment)	Biosantech	Phase I/II	March 2016
THV01 (lentiviral vector-based therapeutic vaccine)	NCT02054286 (closed to enrollment)	Theravectys S.A.	Phase I/II	March 2019
Ad26.Mos.HIV + MVA-Mosaic	NCT02919306 (closed to enrollment)	Janssen Vaccines & Prevention B.V.	Phase I	May 2019
Recombinant adenovirus type 5 vaccine	NCT02762045	Centers for Disease Control and Prevention, China	Phase I	December 2017
iHIVARNA-01 (TriMix & HIV antigen naked messenger RNA)	NCT02413645 (closed to enrollment)	Biomedical Research Institute August Pi i Sunyer (IDIBAPS)	Phase I	October 2016
MAG-pDNA + rVSV_{IN} HIV-1 Gag (DNA + viral vector vaccines)	NCT01859325 (closed to enrollment)	NIAID/Profectus Biosciences, Inc.	Phase I	November 2016

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
TRADITIONAL CHINESE MEDICINE				
Triptolide wilfordii	NCT02219672	Peking Union Medical College	Phase III	July 2017
TREATMENT INTENSIFICATION/EARLY TREATMENT				
LEOPARD: Latency and early neonatal provision of antiretroviral drugs clinical trial	NCT02431975	Columbia University	Not listed	July 2020
New Era Study: Treatment with multi-drug class (MDC) HAART	NCT00908544 (closed to enrollment)	MUC Research GmbH	Not listed	November 2019
Antiretroviral regime for viral eradication in newborns	NCT02712801	National Center for Women and Children's Health, China CDC	Phase IV	December 2018
DGVTRU: Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection	NCT02656511	UCSF	Phase IV	January 2018
DIORR: Dolutegravir impact on residual replication	NCT02500446 (closed to enrollment)	University of Melbourne	Phase IV	December 2016
DRONE: Impact of starting a dolutegravir-based regimen on HIV-1 proviral DNA reservoir of treatment naïve and experienced patients	NCT02370979	University Hospital, Strasbourg, France	Phase IV	July 2017
AAHIV: Antiretroviral therapy for acute HIV infection	NCT00796263	South East Asia Research Collaboration with Hawaii	Phase III	July 2019
tenofovir/emtricitabine + dolutegravir or tenofovir/emtricitabine + darunavir/cobicistat	NCT02987530 (not yet open for enrollment)	French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	Phase III	December 2019
VIRECURE: Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection	NCT02588820	David Garcia Cinca, Hospital Clinic of Barcelona	Phase III	May 2017
EIT: Early infant HIV treatment in Botswana	NCT02369406	Harvard School of Public Health	Phase II/III	February 2019
EARLIER: Early ART to limit infection and establishment of reservoir	NCT02859558	AIDS Clinical Trials Group	Phase II	December 2019
peginterferon alfa-2b	NCT02227277	The Wistar Institute	Phase II	January 2018
peginterferon alfa-2b	NCT01935089 (closed to enrollment)	University of Pennsylvania/Wistar Institute	Phase II	July 2016

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)				
alpha interferon intensification	NCT01295515 (closed to enrollment)	NIAID	Phase I/II	January 2020
IMPAACT P1115: Very early intensive treatment of HIV-infected infants to achieve HIV remission	NCT02140255	IMPAACT/NIAID/NICHD	Phase I/II	April 2022

Table 2. Observational Studies

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
ACTG A5321: Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study	Not listed yet, see ACTG website entry for information	AIDS Clinical Trials Group	N/A	N/A
Analytic treatment interruption (ATI) to assess HIV cure	NCT02437526 (enrolling by invitation only)	Mayo Clinic	N/A	May 2020
Biomarkers to predict time to plasma HIV RNA rebound	NCT03001128	AIDS Clinical Trials Group	N/A	December 2020
CLEAC: Comparison of late versus early antiretroviral therapy in HIV-infected children	NCT02674867	French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	N/A	December 2018
CODEX (the “Extreme” cohort)	NCT01520844	Inserm/ANRS	N/A	February 2018
Effects of dolutegravir based regimen on HIV-1 reservoir and immune activation	NCT02557997	University Hospital, Strasbourg, France	N/A	September 2016
EPIC4: Early Pediatric Initiation: Canada Child cure Cohort Study	CTN S 281	Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS)	N/A	December 2018
Establish and characterize an acute HIV infection cohort in a high-risk population	NCT00796146	Southeast Asia Research Collaboration with Hawaii/Armed Forces Research Institute of Medical Sciences/Thai Red Cross AIDS Research Centre	N/A	July 2019

Table 2. Observational Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
EURECA: Exploratory study of cellular reservoirs in blood	NCT02858414	Centre Hospitalier Universitaire de Besancon	N/A	December 2016
Genotyping FcγRs genes	NCT03130296	University Hospital, Strasbourg, France	N/A	April 2020
HEATHER: HIV reservoir targeting with early antiretroviral therapy	UK CPMS17589 (link currently broken)	University of Oxford/Medical Research Council/British HIV Association	N/A	September 2019
HIV-STAR: HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir	NCT02641756 (closed to enrollment)	University Hospital, Ghent	N/A	December 2019
Host & viral factors associated with HIV elite control	UK CPMS16146 (link currently broken)	University College London Hospitals NHS Foundation Trust	N/A	May 2021
HSCT-HIV: Allogeneic hematopoietic stem cell transplantation in HIV-1 infected patients	NCT02732457	Kirby Institute	N/A	September 2019
ImmunoCo27: Co-adaptation between HIV and CD8 cellular immunity	NCT02886416	French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	N/A	September 2018
Impact of ART adherence on HIV persistence and inflammation	NCT02797093	University of Colorado, Denver	N/A	September 2017
ISALA: Analytical treatment interruption in HIV positive patients	NCT02590354	Institute of Tropical Medicine, Belgium	N/A	November 2017
LoViReT: Low viral reservoir treated patients	NCT02972931 (not yet open for enrollment)	IrsiCaixa	N/A	December 2017
Post analytic treatment interruption study	NCT02761200	South East Asia Research Collaboration with Hawaii	N/A	June 2020
Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans	NCT02154035	NIAID	N/A	December 2019
TESOVIR: Tracking and exploring the source of viral rebound (ART interruption)	NCT03117985	Centre Hospitalier Régional d'Orléans	N/A	February 2018
The use of leukapheresis to support HIV pathogenesis studies	NCT01161199	University of California, San Francisco	N/A	July 2020

Table 3. Completed Studies

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
ADOPTIVE IMMUNOTHERAPY				
Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion	NCT02231281	Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University	Phase III	N/A
ANTIBODIES				
CHERUB 001 Intravenous immunoglobulin in primary HIV infection	No clinicaltrials.gov entry	CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC)	N/A	CROI 2017, Abstract 324
3BNC117	NCT02018510	Rockefeller University	Phase I	Nature. 2015 Jun 25;522(7557):487-91
VRC01	NCT02411539	NIAID	Phase I	N/A
VRC01	NCT02463227	NIAID	Phase I	N Engl J Med. 2016 Nov 24;375(21):2037-2050 CROI 2016, Abstract 32LB, Webcast
VRC01	NCT01950325	NIAID	Phase I	Sci Transl Med. 2015 Dec 23;7(319):319ra206
ANTI-FIBROTIC				
ACE inhibitors	NCT01535235	UCSF/amfAR	Phase IV	N/A
ANTIRETROVIRAL THERAPY				
raltegravir or efavirenz + tenofovir + emtricitabine	NCT00734344	University of Alabama at Birmingham	Phase IV	N/A
ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS				
raltegravir + tenofovir + emtricitabine	NCT01025427	University of California, San Francisco	Phase IV	PLoS Pathog. 2013;9(10):e1003691
ASSEMBLY INHIBITOR				
BIT225	ACTRN12612000696897	Biotron Limited	Phase I	J Antimicrob Chemother. 2016 Mar;71(3):731-8

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
COMBINATIONS				
chemotherapy + maraviroc in people with non-Hodgkin lymphoma	NCT02486510	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase 0	Terminated due to futility criteria
ERAMUNE-01 (antiretroviral intensification +/- interleukin-7)	NCT01019551	ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer	Phase II	AIDS. 2016 Jan;30(2):221-30
ERAMUNE-02 (DNA/Ad5 vaccine, ART intensification)	NCT00976404	Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS	Phase II	CROI 2014, Poster abstract 422
Vacc-4x + romidepsin	NCT02092116	Bionor Immuno AS/Celgene	Phase I/II	Lancet HIV 2016, July 7, 2016
Vacc-4x (peptide-based therapeutic vaccine) + lenalidomide	NCT01704781	Bionor Immuno AS	Phase I/II	IAS 2015 Towards an HIV Cure Symposium, Poster Abstract PE61
vorinostat + hydroxychloroquine + maraviroc (VHM)	NCT02475915 NCT02470351 (CNS substudy)	South East Asia Research Collaboration with Hawaii	Phase I/II	AIDS 2016, Abstract TUAX0101LB
MVA-B (viral vector vaccine) +/- disulfiram	NCT01571466	Hospital Clinic of Barcelona/HIVACAT	Phase I	J Antimicrob Chemother. 2015 Feb 26. pii: dkv046. PLoS One. 2015 Nov 6;10(11):e0141456.
GENE THERAPIES				
SB-728-T	NCT01252641	Sangamo BioSciences	Phase I/II	N/A
SB-728-T	NCT01044654	Sangamo BioSciences	Phase I	ICAAC 2014, Abstract H-643 ; 2013, Abstract H-1464c
SB-728-T	NCT00842634	Sangamo Biosciences/University of Pennsylvania	Phase I	N Engl J Med. 2014 Mar 6;370(10):901-10
Redirected high affinity Gag-specific T cells	NCT00991224	University of Pennsylvania/Adaptimmune	Phase I	N/A
HGTV43	No clinicaltrials.gov entry	Enzo Biochem	Phase I	AIDS 2006, Abstract MOPDA06
IMMUNE CHECKPOINT INHIBITORS				
BMS-936559 (anti-PD-L1 antibody)	NCT02028403	National Institute of Allergy and Infectious Diseases (NIAID)	Phase I	CROI 2016, Abstract 25, Webcast

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
IRON CHELATORS				
deferiprone	NCT02456558	ApoPharma	Phase I	N/A
LATENCY-REVERSING AGENTS				
disulfiram (acetaldehyde dehydrogenase inhibitor)	NCT01286259	University of California, San Francisco/ Johns Hopkins University/amfAR	Not specified	Clin Infect Dis. 2014 58 (6): 883–90
vorinostat (HDAC inhibitor)	NCT01365065	Bayside Health/Merck	Phase II	PLoS Pathog. 2014;10(10):e1004473
valproic acid (HDAC inhibitor)	NCT00289952	McGill University/Canadian Foundation for AIDS Research/CIHR Canadian HIV Trials Network	Phase II	HIV Med. 2012 May;13(5):291–6
valproic acid	NCT00614458	University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme Corp.	Phase II	PLoS One. 2010 5(2): e9390
MGN1703 toll-like receptor 9 (TLR-9) agonist	NCT02443935	University of Aarhus	Phase Ib/IIa	Clin Infect Dis. 2017 Mar 9
Chidamide (HDAC inhibitor)	NCT02513901	Tang-Du Hospital	Phase I/II	N/A
disulfiram	NCT01944371	University of California, San Francisco/Monash University/amfAR	Phase I/II	CROI 2015, Poster abstract 428LB
panobinostat (HDAC inhibitor)	NCT01680094	University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR	Phase I/II	The Lancet HIV. 2014 Oct; 1(1): e13–e21 CROI 2015, Abstract 109, Webcast
vorinostat	NCT01319383	University of North Carolina at Chapel Hill/NIAID/Merck	Phase I/II	Nature. 2012 Jul 25;487(7408):482-5 J Infect Dis. 2014 Sep 1;210(5):728-35
bryostatatin 1 (PKC agonist)	NCT02269605	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase I	AIDS. 2016 Feb 17. [Epub ahead of print]
OBSERVATIONAL STUDIES				
ANRS EP 44: Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)	NCT01038401	French National Agency for Research on AIDS and Viral Hepatitis	N/A	N/A
CHERUB 003 (prospective HIV chemotherapy cohort study)	NCT01902693	Imperial College London/CHERUB	N/A	N/A

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
OBSERVATIONAL STUDIES (Cont.)				
HIV resistance and treatment strategies	NCT00581802	NIAID	N/A	N/A
In vitro autologous vaccine development to activate HIV reservoirs	UK CPMS17532 (link currently broken)	Imperial College London/amfAR	N/A	N/A
MUCOVIR: Exploration of HIV reservoirs	NCT01019044	Objectif Recherche Vaccins SIDA	N/A	JAIDS. 2013 Mar 1;62(3):255-9
Size of the HIV-1 reservoir and ongoing replication in defined cohorts	UK CPMS16004 (link currently broken)	University College London/amfAR	N/A	N/A
Tat protein vaccine (roll-over observational study for extended follow-up of volunteers in the ISS T-003 trial)	NCT02712489	Barbara Ensoli, MD, Istituto Superiore di Sanità/Italian Ministry of Foreign Affairs	N/A	N/A
Tissue drug levels of HIV medications	NCT01490346	University of Minnesota – Clinical and Translational Science Institute/NIAID	N/A	Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.
ULTRASTOP (Towards HIV Functional Cure) ERAMUNE-03 (antiretroviral treatment interruption)	NCT01876862	Objectif Recherche VACCin Sida (ORVACS)/Fondation Bettencourt Schueller	N/A	AIDS, Published Ahead-of-Print, January 4, 2016
VIRECT: Impact of pre-ART CD4 T cell level on the rectal reservoir in long-term HIV-1 treated men	NCT02526940	Centre Hospitalier Universitaire de Saint Etienne	N/A	N/A
THERAPEUTIC VACCINES				
AGS-004 (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)	NCT00672191	Argos Therapeutics	Phase IIb	J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8
AGS-004	NCT01069809	Argos Therapeutics	Phase IIb	IAS 2015 Towards an HIV Cure Symposium, Combination Therapy Trials Roundtable CROI 2014, Poster abstract 344
DermaVir (topically applied DNA vaccine)	NCT00711230	Genetic Immunity	Phase II	N/A
DermaVir	NCT00918840	Genetic Immunity	Phase II	N/A

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
GSK Biologicals HIV Vaccine 732462 (p24-RT-Nef-p17 fusion protein vaccine)	NCT01218113	GlaxoSmithKline	Phase II	Medicine (Baltimore). 2016 Feb;95(6):e2673
Tat protein vaccine	NCT01513135	Barbara Ensoli, MD, Istituto Superiore di Sanità/Italian Ministry of Foreign Affairs	Phase II	N/A
Tat protein vaccine	NCT01513135	Barbara Ensoli, MD, Istituto Superiore di Sanità	Phase II	Retrovirology. 2015 Apr 29;12(1):33 PLoS One. 2010 Nov 11;5(11):e13540
Vacc-4x (peptide-based vaccine)	NCT00659789	Bionor Immuno AS	Phase II	Lancet Infect Dis. 2014 Apr;14(4):291-300
VAC-3S (peptide-based vaccine)	NCT01549119	InnaVirVax	Phase I/IIa	30 Years of HIV Science, 2013, poster abstract 145 IAS 2015 Towards an HIV Cure Symposium, Poster Abstract PE67 LB
AGS-004	NCT02042248	University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH)	Phase I/II	N/A
Autologous HIV-1 ApB DC Vaccine	NCT00510497	Sharon Riddler, University of Pittsburgh/NIAID	Phase I/II	J Infect Dis. 2016 May 1;213(9):1400-9
Dendritic cells pulsed with chemically inactivated HIV	NCT02766049	University of Sao Paulo General Hospital	Phase I/II	J Int AIDS Soc. 2014 Jan 10;17:18938 J. Cellular Immunotherapy xx (2016) 1-10
Dendritic cell vaccine	NCT00833781	Massachusetts General Hospital	Phase I/II	N/A
Dendritic cell vaccine (DCV-2)	NCT00402142	Hospital Clinic of Barcelona	Phase I/II	Sci Transl Med. 2013 Jan 2;5(166):166ra2
DermaVir	NCT00270205	AIDS Clinical Trials Group	Phase I/II	JAIDS. 2013 Dec 1;64(4):351-9

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
GTU®-MultiHIV B Clade Vaccine	NCT02457689	Imperial College London	Phase I/II	N/A
TUTI-16 (synthetic HIV-1 Tat epitope vaccine)	NCT01335191	Thymon, LLC	Phase I/II	Hum Vaccin Immunother. 2012 Oct;8(10):1425-30
Vacc-C5 (peptide-based vaccine)	NCT01627678	Bionor Immuno AS	Phase I/II	N/A
AFO-18 (peptide-based vaccine)	NCT01141205	Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase I	AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12
AFO-18 (peptide-based vaccine)	NCT01009762	SSI/Rigshospitalet/Hvidovre University Hosp./Ministry of Interior & Health, Denmark	Phase I	Clin Immunol. 2013 Feb;146(2):120-30
AT20-KLH	MED-AT20-001	Medestea Research & Production SpA, Turin	Phase I	Vaccine. 2014 Feb 19;32(9):1072-8
ChAdV63.HIVcons + MVA.HIVconsv (viral vector vaccines)	NCT01712425	IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford	Phase I	IAS 2015, Poster abstract MOPEA036
Dendritic cells loaded with HIV-1 lipopeptides	NCT00796770	Baylor Research Institute/ANRS	Phase I	Retrovirology 2012, 9(Suppl 2):P328
DermaVir	NCT00712530	Genetic Immunity	Phase I	PLoS One. 2012 7(5): e35416
D-GPE DNA + M-GPE MVA (DNA + viral vector vaccines)	NCT01881581	Centers for Disease Control and Prevention, China	Phase I	N/A
HIVAX (lentiviral vector-based therapeutic vaccine)	NCT01428596	GeneCure Biotechnologies	Phase I	Vaccine. 2016 Apr 27;34(19):2225-32
HIV-v (peptide-based vaccine)	NCT01071031	PepTcell Limited	Phase I	Vaccine. 2013 Nov 19;31(48):5680-6
JS7 DNA + MVA62B (DNA + viral vector vaccines)	NCT01378156	GeoVax, Inc.	Phase I	HIV R4P 2014, Abstract OA05.03 (webcast)
MAG pDNA vaccine +/- IL-12	NCT01266616	NIAID	Phase I	N/A

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
THERAPEUTIC VACCINES (Cont.)				
MVA.HIVconsv	NCT01024842	University of Oxford/Medical Research Council	Phase I	N/A
PENNVAX-B (Gag, Pol, Env) + electroporation	NCT01082692	Inovio Pharmaceuticals	Phase I	Retrovirology 2012, 9(Suppl 2):P276
PENNVAX-B +/- IL-12 or IL-15	NCT00775424	University of Pennsylvania	Phase I	N/A
TREATMENT INTENSIFICATION/EARLY TREATMENT				
Anti-HIV medications for people recently infected with HIV	NCT00106171	NIAID	Phase IV	PLoS One. 2015 10(11):e0143259
enfuvirtide	NCT00051831	NIAID	Not listed	J Infect Dis. 2010 Jan 15;201(2):293–6
enfuvirtide	NCT00334022	Canadian Immunodeficiency Research Collaborative	Not listed	N/A
PLUS: Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut	NCT00884793	University of California, San Francisco	Not listed	J Infect Dis. 2010 Nov 15;202(10):1553–61 AIDS. 2010 Oct 23;24(16):2451–60
ANRS 147 OPTIPRIM: Optimization of primary HIV-1 infection treatment	NCT01033760	French National Institute for Health and Medical Research–French National Agency for Research on AIDS and Viral Hepatitis (Inserm–ANRS)	Phase III	PLoS One. 2013; 8(5): e64219. PLoS One. 2013; 8(3): e59767 IAS 2013, Abstract WEAB0101 IAS Cure Symposium, Presentation
maraviroc	NCT00808002	Germans Trias i Pujol Hospital	Phase III	AIDS. 2014 Jan 28;28(3):325–34
raltegravir + maraviroc	NCT00935480	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Phase III	N/A
raltegravir	NCT00554398	Germans Trias i Pujol Hospital	Phase III	Antivir Ther. 2012;17(2):355–64
Intense acute infection study	NCT01154673	University of Toronto	Phase II/III	N/A

Research Toward a Cure May 16, 2017

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/Sponsor(s)	Phase	Published/Presented Data
TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)				
maraviroc	NCT00795444	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer	Phase II	PLoS One. 2011; 6(12):e27864 AIDS. 2013 Aug 24; 27(13):2081-8.
raltegravir	NCT00520897	Canadian Immunodeficiency Research Collaborative	Phase II	AIDS. 2012 Jan 14;26(2):167-74
raltegravir	NCT00807443	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal	Phase II	AIDS. 2012 Sep 24;26(15):1885-94
Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection	NCT02614950	South East Asia Research Collaboration with Hawaii	Phase II	CROI 2017, Abstract 124, Webcast
indinavir + zidovudine + lamivudine + nevirapine	NCT00001644	NIAID	Phase I	N/A